Edition:
United States

Vical Inc (VICL.OQ)

VICL.OQ on NASDAQ Stock Exchange Global Select Market

2.33USD
7 Dec 2016
Change (% chg)

-- (--)
Prev Close
$2.33
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
6,315
52-wk High
$4.79
52-wk Low
$2.27

Latest Key Developments (Source: Significant Developments)

Vical Q2 loss per share $0.14
Tuesday, 9 Aug 2016 06:30am EDT 

Vical Inc : Q2 loss per share $0.14 . Vical reports second quarter 2016 financial results . Q2 revenue $4.1 million versus $4.2 million .Projecting net cash burn for 2016 between $8 million and $11 million.  Full Article

Vical announces $7.8 mln equity investment by partner Anges MG
Monday, 1 Aug 2016 06:30am EDT 

Vical Inc : Vical announces $7.8 million equity investment by partner, Anges MG . Shares are being sold at a price of $4.24 per share .With new investment, Anges' equity position in Vical will increase from 2.4% to approximately 18.6% of Vical's outstanding shares.  Full Article

Vical's phase 1/2 trial data shows bivalent vaccine imparts reduction in genital herpes lesions durable to 9 months
Monday, 20 Jun 2016 11:15am EDT 

Vical Inc : Initial top line 3-month data announced in june 2015 showed neither monovalent nor bivalent vaccine met primary endpoint of viral shedding rate reduction from baseline . Vaccine achieved statistically significant reduction in prospectively defined secondary endpoint of genital lesion rate at 3 months versus baseline . Plan to initiate a phase 2 trial of bivalent vaccine during second half of 2016 . Maintain our guidance for net cash burn of between $8 million and $11 million during 2016 .Vical's phase 1/2 trial data presented at asm 2016 shows bivalent vaccine imparts reduction in genital herpes lesions durable to 9 months.  Full Article

Vical Inc says FDA Grants Vical Orphan Drug Designation for VL-2397
Wednesday, 6 Jan 2016 06:30am EST 

Vical Inc:Says FDA Grants Vical Orphan Drug Designation for VL-2397 for the Treatment of Invasive Aspergillosis.Plan to initiate a Phase 1 clinical trial in the first half of 2016.  Full Article

Vical Inc reports top-line results from phase 1/2 trial of therapeutic genital herpes vaccine
Monday, 22 Jun 2015 04:11pm EDT 

Vical Inc:Says the primary endpoint of shedding rate was not met.Says both the monovalent and bivalent vaccines were generally well tolerated.Says are also moving our in-licensed antifungal compound toward a phase 1 trial initiation during the first half of 2016.Enrollment is complete in the phase 2 solid organ transplant trial;on track for data during the second half of 2016.Bivalent vaccine achieved statistically significant reductions in the rate of genital lesions.  Full Article

Vical Inc and AnGes MG announce collaboration to develop therapy for ebola virus disease
Wednesday, 14 Jan 2015 04:59am EST 

Vical Inc and AnGes MG:They have entered into collaboration.To develop and commercialize an equine polyclonal antibody therapy for patients afflicted with Ebola virus disease.No medicines or vaccines are currently approved for treatment of Ebola.  Full Article

BRIEF-Vical reports Q3 loss per share $0.24

* Vical Inc says projecting net cash burn for 2016 between $8 million and $11 million